Keywords
Systemic Lupus Erythematosus
Rituximab
pediatrics
How to Cite
Abstract
Systemic Lupus Erythematosus (SLE) is an autoimmune disease with multisystemic involvement and unpredictable course. Diffuse alveolar hemorrhage (HAD) is a rare and potentially fatal manifestation, and should therfore be considered as a differential diagnosis in patients with pulmonary symptoms. We report the case of a previously healthy 14-year-old girl with severe and refractory diffuse alveolar hemorrhage as the initial manifestation of SLE who was treated effectively with Rituximab (RTX). Currently there are no standardized protocols for these specific cases, so treatment remains individualized. This report supports recent pathophysiologic knowledge of the use of RTX in severe or refractory cases.
References
(1) Kazzaz NM, Coit P, Lewis EE, et al. Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival. Lupus Science & Medicine 2015;2:e000117.
(2) Kim D, Choi J, Cho SK, Choi CB, Kim TH, Jun JB, et al. Clinical characteristics and outcomes of diffuse alveolar hemorrhage in pa- tients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017 Jun;46(6):782-787.
(3) Zamora MR, Warner ML, Tuder R, et al. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997;76:192–202.
(4) C. Ednalino, J. Yip, and S. E. Carsons, “Systematic review of diffuse alveolar hemorrhage in systemic lupus erythematosus: focus on outcome and therapy,” Journal of Clinical Rheumatology, vol. 21, no. 6, pp. 305–310, 2015.
(5) Silva CA, Blay G, Rodrigues JC, Leal GN, Ferreira JC, Novak G, et al. (2017, junio). Diffuse alveolar hemorrhage: A multicenter study in 847 childhood-onset systemic lupus erithematosus patients. Póster presentado al Annual European Congress of Rheumatology: EULAR 2017, Madrid, España.
(6) Tse JR, Schwab KE, McMahon M, Simon W. Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus. Lupus. 2015 Jun;24(7):756-9.
(7) Pottier V, Pierrot M, Subra JF, Mercat A, Kouatchet A, Parrot A, et al. Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage. Lupus. 2011 May;20(6):656-9.
(8) Montes-Rivera G, Ríos G, Vilá L. Efficacy of Rituximab in a Systemic Lupus Erythematosus Patient Presenting with Diffuse Alveolar Hemorrhage. Case Rep Rheumatol. 2017; 2017: 6031053.
(9) Verzegnassi F, Marchetti F, Zennaro F, et al. Prompt efficacy of plasmapheresis in a patient with systemic lupus erythematosus and diffuse alveolar haemorrhage. Clin Exp Rheumatol 2010; 28:445–6.
(10) Ta R, Celli R, West AB. Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: Histopathologic Features and Clinical Correlations. Case Rep Pathol. 2017;2017:1936282.
(11) Zhuang H, Han S, Lee PY, Khaybullin R, Shumyak S, Lu L, Chatha A. Pathogenesis of Diffuse Alveolar Hemorrhage in Murine Lupus. Arthritis Rheumatol. 2017 Jun; 69(6):1280-1293.